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Abstract
Background: The prognosis for many cancers could be improved dramatically if they could be detected while still at
the microscopic disease stage. It follows from a comprehensive statistical analysis that a number of antigens such as
hTERT, PCNA and Ki-67 can be considered as cancer markers, while another set of antigens such as P27KIP1 and FHIT
are possible markers for normal tissue. Because more than one marker must be considered to obtain a classification of
cancer or no cancer, and if cancer, to classify it as malignant, borderline, or benign, we must develop an intelligent
decision system that can fullfill such an unmet medical need.
Results:  We have developed an intelligent decision system using machine learning techniques and markers to
characterize tissue as cancerous, non-cancerous or borderline. The system incorporates learning techniques such as
variants of support vector machines, neural networks, decision trees, self-organizing feature maps (SOFM) and recursive
maximum contrast trees (RMCT). These variants and algorithms we have developed, tend to detect microscopic
pathological changes based on features derived from gene expression levels and metabolic profiles. We have also used
immunohistochemistry techniques to measure the gene expression profiles from a number of antigens such as cyclin E,
P27KIP1, FHIT, Ki-67, PCNA, Bax, Bcl-2, P53, Fas, FasL and hTERT in several particular types of neuroendocrine tumors
such as pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and
hyperplasia (ACH) involved with Cushing's syndrome. We provided statistical evidence that higher expression levels of
hTERT, PCNA and Ki-67 etc. are associated with a higher risk that the tumors are malignant or borderline as opposed
to benign. We also investigated whether higher expression levels of P27KIP1 and FHIT, etc., are associated with a
decreased risk of adrenomedullary tumors. While no significant difference was found between cell-arrest antigens such
as P27KIP1 for malignant, borderline, and benign tumors, there was a significant difference between expression levels of
such antigens in normal adrenal medulla samples and in adrenomedullary tumors.
Conclusions: Our frame work focused on not only different classification schemes and feature selection algorithms, but
also ensemble methods such as boosting and bagging in an effort to improve upon the accuracy of the individual classifiers.
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It is evident that when all sorts of machine learning and statistically learning techniques are combined appropriately into
one integrated intelligent medical decision system, the prediction power can be enhanced significantly. This research has
many potential applications; it might provide an alternative diagnostic tool and a better understanding of the mechanisms
involved in malignant transformation as well as information that is useful for treatment planning and cancer prevention.
Background
The National Cancer Institute and National Human
Genome Research Institute, both part of the NIH and U.S.
Department of Health and Human Services, have
launched The Cancer Genome Atlas (TCGA) with an over-
arching goal of understanding the molecular basis of can-
cer to improve our ability to diagnose, treat and prevent
cancer. The perspective of the TCGA project is that “cancer
is not a single disease but a collection of diseases that arise
from different combinations of genetic changes. Scientists
must be able to analyze the genetic material from different
tumors and many patients to uncover the tell-tale genetic
signatures of different cancer types.” (http://cancerge
nome.nih.gov). Based on the mission of TCGA, we have
proposed a further parallel paradigm on cancer: it is not
only the genetic changes (i.e. mutations of genes) but
changes of gene expressions and regulatory networks that
are ultimately responsible for cancer development. Under
this parallel paradigm, mutations of genes and un-
mutated genes with differential expressions and alterna-
tive splicing cause changes in gene regulatory networks
(that also cause cancer) when cells are subjected to unu-
sual environments. We consider that the differences
between cancer and normal tissue are small in terms of
their genotype but perhaps quite larger when one factors
in the correlated “biological behaviour phenotypes.”
Therefore, our approach focuses on the investigation of
differential expressions of genes among normal, benign
and cancerous tissues in addition to the genome-wide sur-
vey of cancer genetics.
According to the NHGRI-NIH, the cost to sequence
genomes will be covered by major insurance policies.
Given this, the era of affordable patient-specific medicine
based on the full complement of genes is not too far away.
However, highly characteristic cancer marker(s) may not
always exist in individual patients because, even for the
same type of cancer, the genetic mechanisms may be dif-
ferent. The human genome is abundant with alternative
splicing; the same gene might have different protein prod-
ucts.
Our novel medical decision system accounts for this vari-
ety by using differential gene expression levels. We devel-
oped it using Cushing's syndrome as a condition upon
which to test pilot our discoveries that challenge today's
pathological and histological methods. Once tested, our
intelligent medical decision system achieved 92.6% accu-
racy on three types of Cushing's syndrome, indicating that
the joint use of differential gene expressions has enhanced
our ability to diagnose diseases. Our long-term strategy is
to investigate differential gene expression levels and regu-
latory pathways that may lead to cancer. The goal of this
paper is to introduce a medical decision system as well as
the tumor-associated gene expressions that are behind it.
These expressions—once expanded upon—will further
improve the system and move it beyond the diagnosing of
Cushing's syndrome to other types of tumors.
Cushing's syndrome also called hypercortisolism or
hyperadrenocorticism is a common endocrine disorder
caused by excessive levels of the endogenous corticoster-
oid hormone cortisol, which is secreted by the adrenal
glands which are in turn related to the regulations by the
pituitary gland and hypothalamus in the brain. Cushing's
syndrome refers to excess cortisol regardless of its etiol-
ogy. More than two-thirds of cases are related to Cushing's
disease, a syndrome characterized by hypercortisolism
secondary to excess production of adrenocorticotropin
(ACTH) from a pituitary gland adenoma. Roughly one-
fourths cases are Cushing's syndrome that is a group of
adrenocortical diseases that include tumors of adrenocor-
tical carcinoma (ACC), adrenocortical adenoma (ACA)
and adrenocortical hyperplasia (ACH) that all lead to
hypercortisolism. The rest of excessive production of
ACTH induced by other cancers such as lung cancer and
external sources that cause the symptoms of Cushing’s
syndrome are rare (less than 10%). Most of those adren-
ocrtical tumors are benign, however roughly one-quarter
may metastasize. The distinctions among Cushing syn-
drome cases under pathological analysis may not be obvi-
ous or not clinically detectable at all, yet the treatments
and prognosis are not only different, but also very often
determined inappropriately. Cushing's syndrome, there-
fore, is a complicated disease type, mainly classified as
neuroendocrine tumors, that are, in of themselves, gener-
ally difficult to identify as potential malignancies based
on clinical symptoms and pathological features [1-4]. To
conquer such difficulties, we conducted a survey of
human genome and tumor genetics and identified several
useful (potential) markers such as the expression profiles
of cyclin E, P27kip1, FHIT, Bax, Fas, FasL, PCNA, hTERT
and Ki-67 for types of Cushing's syndrome. We selected
FHIT, PCNA, and Ki-67 because we consider these 3 mark-
ers as the most important and easily managed, given ourBMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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limited experimental supports as illustrated in the follow-
ing:
Tumor behaviour and growth are considerably influenced
by the expressions of two types of genes in the human
genome: the cell proliferating genes (for instance, Ki-67
[6,13] and PCNA) and tumor suppressor genes (for exam-
ple FHIT).
Recently, the protein-coding gene FHIT (fragile histidine
triad) has been identified at chromosomal region 3p14.2.
While the biological function of the FHIT in the human
genome has not been fully characterized yet, it is known
that deletion and the degree of deletion in the gene
expression level of FHIT are closely associated to the
malignancies and prognosis of variety of human tumors
[5,6]. Therefore, FHIT is considered a tumor suppressor.
Malignant tumors are showing necrosis and uncontrolled
cell proliferation that is related to a nuclear antigen called
Ki-67, a nonhistone nucleoprotein in proliferating cell
nuclei. This polypeptide accumulates from G1 -phase to
mitosis [7-10]. The role of Ki-67 in the human genome
has not been identified but Ki-67 antigen-positive cells
have given a more accurate indication of proliferating
cells compared to that of PCNA (Proliferating Cell
Nuclear Antigen) positive cells in many cancers as PCNA
is detectable in almost all quiescent cells adjacent to some
tumors. Therefore, Ki-67 is a proliferation antigen which
is expressed during all phases of the cell cycle except for
the resting of cells in G0. The Ki-67 labelling index has
prognostic significance in various types of carcinomas,
including ACC in Cushing's syndrome. We measure the
expression of Ki-67 as a potential malignant tumor
marker.
Proliferation cell nuclear antigen (PCNA) was originally
identified as an antigen that is expressed in the nuclei of
cells during the DNA synthesis phase of the cell cycle. In
human genome, PCNA is protein-coding gene product of
a kind of ploy-peptide-in-nuclei that acts as processivity
for DNA polymerase delta in eukaryotic cells. This pro-
tein-coding gene is highly expressed only in proliferating
cells. PCNA helps hold DNA polymerase delta (Pol δ) to
DNA. PCNA is clamped to DNA through the action of rep-
lication factor C (RFC). In human genome, the expression
of PCNA is under the control of E2F transcription factor-
containing complexes Therefore, the expression and the
protein product of PCNA are linked to the cell cycle. In
many cases, PCNA can be used to judge malignancies of
various tumors and their degrees of proliferation [11-14];.
Our immunohistochemical experiments that measure the
expression levels of gene-coding proteins Ki-67 and PCNA
confirmed their roles in cell cycle regulation and cell pro-
liferation. Since a highly characteristic malignant marker
(say 90% accuracy) has not been found in any neuroen-
docrine tumors, we therefore developed an integrated
medical decision machine using a number of associated
markers to predict malignancies and to diagnose different
adrenocortical diseases, using FHIT, Ki-67 and PCNA as
features in the input space.
Results
Patients and tumor samples
The tumor samples were from surgical removals of “visi-
ble tumors” of patients at the first affiliated hospital of
Guanxi Medical University from 1995 to 2005 and were
all paraffin embedded and well preserved. All samples
were careful determined by all means of pathological and
histological analyses. There are 49 confirmed cases of
adrenocortical diseases: they are 14 cases of adrenocorti-
cal carcinoma (ACC), 26 cases of adrenocortical adenoma
(AC A) and 9 cases of adrenocortical hyperplasia (ACH).
All cases have been verified by individual patients' medi-
cal records. Nineteen of the samples were from male
patients (37.5%), and 30 were from female patients
(62.5%). The average age and standard deviation of the
patients was 35.84±16.18 years. Typical clinical symp-
toms, signs and laboratory findings of Cushing's syn-
drome were observed in all cases (Tables 1 and 2). Low-
dose dexamethasone suppression test were not inhibited
in all cases.
Measuring protein coding gene expression levels
Although the immunohistochemical measurements of
gene express levels of the antigens are not considered as
highly quantitative compared to other expensive methods
such as DNA microarray, FISH (fluorescent in situ hybrid-
ization) and measuring mRNA by in situ hybridizations
using cDNA probes via quantitative Reverse Transcriptase
Polymerase Chain Reaction (RT-PCR), the immunohisto-
chemistry is very affordable and the results barely affect
the performance of our intelligent diagnosis system. We
used FHIT rabbit polyclonal antibody (product of Zhong-
shan Biotechnology, Beijing, China). Ki-67 and PCNA
mouse monoclonal antibody kits (ready-to-use products
of Maixin Biotechnology Development Co. Fuzhou,
China). Immunohistochemical staining was performed
using the Superision TM two-step method. In our experi-
ments, we used known positive sections of corresponding
tissue samples as positive controls (such as stomach tissue
as the positive control for FHIT; gastric cancer as the posi-
tive control for PCNA and breast cancer as the positive
control for Ki-67). Phosphate-buffered saline (PBS) was
used to replace the first antibody and make the “blank”
negative control. The HE dyes were used to make the his-
tological control of samples. Our experiments were per-
formed using standard molecular biology procedures to
measure the intensities of positive staining and positive
rates of the samples by immunohistochemistry: BrownBMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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granules in cell nuclei or cytoplasm are considered as pos-
itive signals. Specifically, to measure the expression level
of FHIT protein in cytoplasm, brown granule in cytoplasm
is a positive signal. To measure the levels of expressions of
Ki-67 and PCNA proteins in nuclei, brown granules in
nuclei are positive signals. The intensities of signals are
graded by staining colors: achromatism is marked as 0,
light yellow is marked as 1, light brown is marked as 2,
and dark brown is marked as 3. Then we compared and
determined the graded levels by percentage of positive
cells in same type cells: positive cell rate < 5% is marked
as 0, positive cell rate between 6%—25% is marked as 1,
positive cell rate between 26% -50% is marked as 2, posi-
tive cell rate between 51%—75% is marked as 3, positive
cell rate > 75% is marked as 4. Then we combined staining
intensities and positive cell rates in same type of cells and
determine the overall expression level: mark 0 is negative
(−), mark 1-4 is weakly positive (+), mark 5-8 is medially
positive (+ +), mark 9-12 is strongly positive (+ + +).
Because Ki-67 protein is in nuclei, brown granules in
nuclei are positive signal. Positive cell rate < 10% is con-
sidered negative (−), positive cell rate between 10%—
25% is weakly positive (+), positive cell rate between
25%—50% is medially-positive (+ +), positive cell rate >
50% is strongly-positive ( + + +). The determination of
those expression levels are also in accordance with [13,15-
19]. The measurements are observed and photographed
using the Pathological Image Analysis System,
DMR+Q550, Germany.
Results and analysis
Patients' information such as sex, age, side (left or right)
or bilateral (if any), diagnosis date, last occurrence; clini-
cal symptoms, abdominal mass, hypertension, central
obesity, moon face, buffalo hump, plethoric face, purple
striae, hairiness, weakness, decrease in bone content, ECG
abnormity and arteriosclerosis, impaired glucose toler-
ance, infections, oligomenorrhea or amenorrhea, edema,
acne, petechia, headache, decrease in bone content, renal
calculi, thin skin, bellyache, myoatrophy have all been
carefully annotated with the data of laboratory findings
such as blood potassium, blood cortisol (8AM, 4PM,
0AM), blood ACTH (8AM, 4PM, 0AM), 24h urinary 17-
OH, 24h urinary 17-KS; medical images such as observed
tumor size by B-ultrasonic tomography, CT, MRI, PET (if
any) and measuring expression levels of protein coding
genes by immunohistochemical staining for FHIT, Ki-67,
and PCNA in adrenocortical diseases have been recorded
and reviewed. All data were then analyzed by a profes-
sional statistical software package called SPSS version
11.5. Probability α = 0.05 is considered as statistically sig-
nificant. We compared measurements by analysis of vari-
ance and rank sum test with paired comparisons and chi-
square goodness-of-fit test. We designed filters by ordinal
logistic regression.
Expression of FHIT in hypercortisolism of various 
adrenocortical diseases results and analysis
Brown granule of FHIT protein in cytoplasm is considered
as positive signal. Among the 14 cases of adrenocortical
carcinoma, the weakly positive rate is 42.86% (6/14),
both medially positive rate and strongly positive rates are
0% (0/14), total positive rate is 42.86% (6/14); the
weakly positive rate in 26 cases of adrenocortical adeno-
mas is 0% (0/26), medially positive rate is 61.54% (16/
26), strongly positive rate is 34.62% (9/26), total positive
rate is 96.15% (25/26), with only 1 case of negative; in 9
cases of adrenocortical hyperplasia, both weakly positive
rate and medially positive rate are 0% (0/9), strongly pos-
itive rate is 100% (9/9), total positive rate is 100% (9/9)
(Figures 1, 2 and 3). It is evident that the expression level
of FHIT decreases while tumor malignancy increases. Sta-
tistically analysis showed that the level of total positive
rate of adrenocortical carcinoma is significantly lower
than both adenoma and hyperplasia (P < 0.0005). There
is no statistical difference of the total positive rate between
adrenocortical adenoma and hyperplasia (P > 0.05).
Comparing the classification of tumors, all cases of adren-
ocortical hyperplasia are strongly positive; in adrenocorti-
cal adenoma, 16 cases are medially positive (61.54%),
and 9 cases are strongly positive (34.62%). There are sta-
tistically significant differences between them (P <
0.0005). The total positive rate of carcinoma is 42.86%.
Six cases of adrenocortical carcinoma are weakly positive,
others are negative. Comparing with classification results,
there are statistically significant differences between
adrenocortical carcinoma and adenoma in negative or
weakly positive expression (P < 0.01), as well as between
adrenocortical carcinoma and adrenocortical hyperplasia
(P < 0.01) (Table 3).
Adrenocortical carcinoma FHIT(−) SuperisionTM two foot- works Figure 1
Adrenocortical carcinoma FHIT(−) SuperisionTM two foot-
worksBMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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Expression of Ki-67 in hypercortisolism of various 
adrenocortical diseases
Ki-67 protein is expressed in cell nuclei. The weakly posi-
tive rate in 14 cases of adrenocortical carcinoma is 50%
(7/14), medially positive rate is 28.57% (4/14), strongly
positive rate is 7.14% (1/14), and total positive rate is
85.71% (12/14). The weakly positive rate in 26 cases of
adrenocortical adenoma is 7.69% (2/26), both medially
positive rate and strongly positive rates are 0% (0/26),
total positive rate is 7.69% (2/26). All the 9 cases of adren-
ocortical hyperplasia are negative. All of the weakly posi-
tive rates, medially positive rates and strongly positive
rates are zero (0/9) (Figures 4, 5 and 6). It is evident that
the expression level of Ki-67 increases as tumor malig-
nancy increases. Total positive rate of adrenocortical carci-
noma is higher than both adenoma and hyperplasia (P <
0.0005). There is no statistically significant difference of
the total positive rate between adrenocortical adenoma
and hyperplasia (P > 0.05). But compared with the classi-
fication of tumors, all adrenocortical hyperplasia cases are
negative; in adrenocortical adenoma, 2 cases are weakly
positive (7.69%), medially and strongly positive are 0%.
There are statistically significant differences between them
(P < 0.0005). Compared with classifications of tumors,
there is a statistically significant difference between adren-
ocortical carcinoma and adenoma in medially and
strongly positive expression (P < 0.0005), as well as
between carcinoma and hyperplasia (P < 0.0005) of medi-
ally and strongly positive signals. The expression level in
adrenocortical carcinoma is higher than that both in ade-
noma and hyperplasia (P < 0.0005) (Table 4). In general,
we consider high expression level of Ki-67 as a malignant
tumor marker. These experimental results indicate that
adrenocortical carcinoma can be considered as a malig-
nant cancer. In fact, although adrenocortical carcinomas,
generally, carry poor prognoses, still often wrongly con-
sidered as benign, the disease is the only occasionally the
Table 2: Expression of FHIT in adrenocortical diseases [n(%)]
Histology
Total
n Negative Positive
(++++)
− ++ + + + +
Carcinoma
6(42.86)
14 8(57.14) 6(42.86) 0(0.00) 0(0.00)
Adenoma
25(96.15)
26 1(3.85) 0(0.00) 16(61.54) 9(34.62)
Hyperplasia
9(100.00)
9 0(0.00) 0(0.00) 0(0.00) 9(100.00)
*χ2=29.948 P<0.0005
Adrenocortical hyperplasia FHIT ( + + +) SuperisionTM two  footworks Figure 3
Adrenocortical hyperplasia FHIT ( + + +) SuperisionTM two 
footworks
Adrenocortical adenoma FHIT (++) SuperisionTM two foot- works Figure 2
Adrenocortical adenoma FHIT (++) SuperisionTM two foot-
works
Table 1: Laboratory findings of hypercortisolism
Item
Blood cortisol (nmol/L)
8AM 846.13±253.995
4PM 748.11±252.344
0AM 633.54±310.857
Blood ACTH (pmol/L)
8AM 5.14±7.08*
4PM 3.99±4.88*
0AM 2.07±4.60*
24h urinary 17-OH (μmol/L) 18.37±11.40*
24h urinary 17-KS (μmol/L) 19.00±8.90*
Blood potassium (nmol/L) 3.48±0.66
PS: data marks * is skew distribution data, shown by median ±quartile
xs ± ()BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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cause of Cushing's syndrome. Five-year disease-free sur-
vival for a complete resection of a Stage I-III ACC (adren-
ocortical carcinoma) is only approximately 30%. Based
on our experimental results, ACC, a common tumor of the
adrenal cortex, should be considered at least potentially
malignant, while adrenocortical hyperplasia is not only
benign but also not considered a tumor but rather an
aggregation of unusual cell clusters. ACA should be con-
sidered as benign though at risk for malignant transforma-
tion.
Expression of PCNA in hypercortisolism of various 
adrenocortical diseases
The expression of protein-coding gene PCNA is only in
cell nuclei. The weakly positive rate in 14 cases of adreno-
cortical carcinoma is 7.14% (1/14), medially positive rate
is 42.86% (6/14), strongly positive rate is 50% (7/14),
and total positive rate is 100% (14/14). The weakly posi-
tive rate in 26 cases of adrenocortical adenomas is 42.31%
(11/26), medially positive rate is 42.31% (11/26),
strongly positive rate is 11.54% (3/26), and total positive
rate is 96.15%(25/26). Only one case is negative. The
weakly positive rate in 9 cases of adrenocortical hyperpla-
sias is 55.56% (5/9), medially positive rate is 22.22% (2/
9), strongly positive rate is 0% (0/9) and total positive rate
is 77.78%(7/9). Two cases are negative (Figures 7, 8 add
9). Those experiments indicate that the level of PCNA
expression increases as tumor malignancy increases. There
is no statistically significant difference in paired compari-
sons of adrenocortical carcinoma, adenoma and hyper-
plasia (P > 0.05). Compared with classification of tumors,
there is a statistically significant difference between ACC
and ACA (P<0.0005), as well as between ACA and ACH
(P<0.0005) of medially and strongly positive signals. The
expression level in ACA is higher than that in ACC and
ACH. Most adrenocortical hyperplasia is negative or
weakly positive. Compared with classification results,
there is a statistical significance between ACH and ACA
(P<0.0005) as well as between ACH and ACC (P<0.0005)
of medially and strongly positive signals. The expression
level of PCNA in adrenocortical hyperplasia is lower than
those in adenoma and carcinoma (Table 5). Those results
do not surprise us because we consider Ki-67 as a better
malignant marker than PCNA, as PCNA is also detectable
in normal tissues adjacent to some tumors. Therefore, it is
Adrenocortical hyperplasia Ki-67(—) SuperisionTM two foot- works Figure 6
Adrenocortical hyperplasia Ki-67(—) SuperisionTM two foot-
works
Adrenocortical carcinoma Ki-67 ( + +) SuperisionTM two  footworks Figure 4
Adrenocortical carcinoma Ki-67 ( + +) SuperisionTM two 
footworks
Adrenocortical adenoma Ki-67 (+) SuperisionTM two foot- works Figure 5
Adrenocortical adenoma Ki-67 (+) SuperisionTM two foot-
worksBMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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also plausible that PCNA is detectable in adrenocortical
hyperplasia. This also indicated that hyperplasia should
not be considered as completely normal tissue rather
transforming to benign tumor. PCNA should not be
detectable in completely normal tissues. When all statisti-
cal analyses are combined into the intelligent diagnostic
system, PCNA is actually a little bit better marker than Ki-
67 for distinguishing ACC, ACA and ACH. Because most
tumors of Cushing's syndrome are benign, nevertheless
Ki-67 must be also included into the system to make a reli-
able diagnosis.
Statistical correlations between the expression levels
Tables 6,7 and 8 show the paired correlations of the
expression levels of FHIT, Ki-67 and PCNA in hypercorti-
solism of adrenocortical diseases (ACC, ACA, ACH). The
correlation between the expression levels of FHIT and Ki-
67 is negative (r = −0.718, P < 0.0005). The correlation
between the expression levels of FHIT and PCNA is nega-
tive (r = − 0.449, P = 0.001). The correlation between the
expression of Ki-67 and PCNA is positive (r = 0.387, P =
0.006).
Table 9 shows that there is no statistically significant dif-
ferences among the expression levels of FHIT, Ki-67,
PCNA in all 49 cases of adrenocortical diseases with
regarding to the clinical parameters including age, sex,
side (left or right) (P > 0.05).
Those results indicate tumor markers FHIT, PCNA, Ki-67
should be used jointly in designing an intelligent medical
decision system to diagnose the different diseases of
Cushing's syndrome as none of the markers is highly char-
acteristic but all are useful.
Analysis of the related factors of hypercortisolism of 
various adrenocortical diseases
In order to study the relationships of hypercortisolism
and clinical parameters, a number of factors have been
screened by ordinal logistic regression. Hypercortisolism
of various adrenocortical diseases, including carcinoma,
adenoma and hyperplasia, are ordinal multivariate data
that can be analyzed by ordinal logistic regression. We
choose the pathologic types (i.e. ACC, AC A, ACH) as
resulting variable Y. Clinical and laboratory parameters
are independent variable X (i.e. FHIT, PCNA, Ki-67). The
quantifying of variables is shown by Table 10 (Table 10
only shows the variables that are statistically significant in
brief due to limitation of the length of this paper).
Single factor ordinal logistic regression analysis
Among the methods of the ordinal logistic regression,
firstly, we performed the single factor ordinal logistic
regression analysis because the clinical factors are over-
whelmingly diverse but the tumor samples are always lim-
ited. We chose the statistically significant level as α < 0.10.
Those factors that have statistical significance in single fac-
tor ordinal logistic regression analysis are entered as mul-
tivariate ordinal logistic regression analysis.
Using the single factor ordinal logistic regression analysis,
we found there are no statistically significant differences
between a number of factors and diagnosis of hypercorti-
solism of various adrenocortical diseases (P > 0.10)
Table 4: Expression of PCNA in adrenocortical diseases [n(%)]
Histology n Negative Positive Total
(++++)
− + ++ +++
Carcinoma
12(85.71)
14 2(14.29) 7(50.00) 4(28.57) 1(7.14)
Adenoma
25(96.15)
26 1(3.85) 11(42.31) 11(42.31) 3(11.54)
Hyperplasia
7(77.78)
9 2(22.22) 5.(55.56) 2(22.22) 0(0.00)
* χ2=29.948 P<0.0005
Table 3: Expression of Ki-67 in adrenocortical diseases [n(%) ]
Histology
Total
n Negative Positive
(++++)
− ++ + + + +
Carcinoma 14 2(14.29) 7(50.00) 4(28.57) 1(7.14) 12(85.71)
Adenoma 26 24(92.31) 2(7.69) 0.(0.00) 0.(0.00) 2(7.69)
Hyperplasia 9 9(100.00) 0.(0.00) 0(0.00) 0.(0.00) 0.(0.00)BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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including but not limited to common clinical informa-
tion such as sex, age, disease on left or right, last time of
disease; clinical symptoms and signs: such as abdominal
mass, hypertension, central obesity, moon face, buffalo
hump, plethoric face, purple striae, hairiness, weakness,
decrease in bone content, ECG abnormity and arterioscle-
rosis, impaired glucose tolerance, infections, oligomenor-
rhea or amenorrhea, edema, acne, petechia, headache,
decrease in bone content, renal calculi, thin skin, belly-
ache, myoatrophy; laboratory findings: such as blood
potassium, blood cortisol (8AM, 4PM, 0AM), blood
ACTH (8AM, 4PM, 0AM), 24h urinary 17-OH, 24h uri-
nary 17-KS; Image findings: such as observed tumor size
by B-ultrasonic tomography, CT, MRI. However there are
statistically significant differences with regarding to
immunohistochemical staining of expression levels of
FHIT, Ki-67, PCNA and a few factors among different
adrenocortical diseases. This indicates that there are statis-
tically significant differences among the diagnosis of
hypercortisolism of various adrenocortical diseases using
differential gene expression levels of FHIT, Ki-67, PCNA
and a few factors that include abdominal mass, decrease
in bone content or fracture, blood cortisol level (4PM),
blood ACTH level (8AM), tumor size, and blood cortisol
level (4PM, P< 0.10, the others P < 0.05) (table 11). We
determined that the above 8 factors are the related factors
in diagnosis of hypercortisolism and are used as features
of our intelligent medical decision system.
Multivariate ordinal logistic regression analysis
Those 8 factors that have statistical significances in single
factor ordinal logistic regression analysis are entered into
multivariate ordinal logistic regression analysis. Factors
sifting are adopted into step-by-step method. We entered
significance level α = 0.05 and eliminated significance
level α = 0.10. We used Chi-Square Goodness-of-Fit test
with a result of χ2 = 9.422, P = 0.991 > 0.05. Multivariate
ordinal logistic regression analysis found that only FHIT
and PCNA are strongly related factors of hypercortisolism
of various adrenocortical diseases. The correlation
between the FHIT and hypercortisolism was negative, the
correlation between the PCNA and hypercortisolism was
positive (Table 12). Ki-67 is the next useful feature while
the rest of the 5 factors are less useful but are not com-
pletely useless. This result appears plausible, yet we con-
sider that Ki-67 is a malignant cancer marker. However
most of Cushing's syndrome are benign tumors and, as
such, it is reasonable that FHIT and PCNA are dominant
Adrenocortical hyperplasia PCNA(—) SuperisionTM Figure 9
Adrenocortical hyperplasia PCNA(—) SuperisionTM
Adrenocortical carcinoma PCNA ( + + +) SuperisionTM two  footworks Figure 7
Adrenocortical carcinoma PCNA ( + + +) SuperisionTM two 
footworks
Adrenocortical adenoma PCNA (+ +) SuperisionTM two  footworks Figure 8
Adrenocortical adenoma PCNA (+ +) SuperisionTM two 
footworksBMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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features to diagnose different types of hypercortisolism in
the intelligent machine. Results also indicate that none of
the 8 factors is highly characteristic; therefore, we
designed an intelligent medical system to enhance the
diagnostic accuracy using those 8 factors jointly as illus-
trated in the following section.
Discussion
The accurate diagnosis of hypercortisolism of various
adrenocortical diseases is very critical for suitable treat-
ment planning because effective treatments differ for the
various forms of disease associated with Cushing's syn-
drome. Accurate diagnosis also determines prognosis.
Based on our clinical experience, there is no universal
effective way to distinguish hypercortisolism among the
various adrenocortical diseases. To counter this reality, we
used comprehensive information that includes the clini-
cal symptoms and signs, the level of biochemical parame-
ters, hormone tests, medial images, pathologic
observation. All of these factors have various limitations
and difficulties. Some cases of hypercortisolism involved
with adrenocortical diseases are extremely difficult to dis-
tinguish based on clinical and pathological analyses. Tra-
ditional methods sometime lead to misdiagnosis and
wrong choices of the therapeutic schedule [21-25]. This
motivated our interest to develop an intelligent medical
decision system utilizing tumor associated gene expres-
sions. The system offers a straightforward accurate diagno-
sis of hypercortisolism of various adrenocortical diseases
and, in doing so, represents a realistic and significant clin-
ical diagnostic tool that is highly in demand in today's
medicine. We used 8 factors namely FHIT, Ki-67, PCNA,
abdominal mass, tumor size, decrease in bone content or
fracture, blood cortisol level (4PM), blood ACTH level
(8AM); as features in our system for differential diagnosis
of hypercortisolism of adrenocortical diseases. FHIH and
PCNA are the two most important features for the system,
followed by Ki-67. The remaining 5 features are useful.
Expression level and significance of FHIT
In the human genome, Fragile histidine triad (FHIT) is a
gene that was determined and cloned by Ohta et al [26]
using Exon acquisition method in 1996. This gene
belongs to histidine triad gene families and is the first
tumor suppressor gene connected to the fragile site [26]
region of 3p14 in human genome. FHIT gene plays a role
in cell cycle regulation and apoptosis [27,28]. FHIT gene
is expressed in normal human cells. Abnormal expres-
sions of the FHIT gene are connected to diverse forms of
malignant tumor development [29-31]. The bioinformat-
ics studies showed that in a great variety of human tumors
or tumor cell lines, the FHIT gene presents frequent
homozygous deletion, loss of heterozygosity (LOH) and
abnormal transcription [32-37]. Furthermore, the bioin-
formatics studies showed diversiform human epithelial
malignancies, FHIT gene absence, abnormal methylation
and deplete of FHIT protein express level contribute 70%
of human cancers relating the functionality of FHIT. It,
thus, can be concluded that FHIT is closely linked to
malignant transformation [38]. For many tumors, abnor-
mal FHIT gene regulatory transcription and FHIT protein
deletion or re-education have been identified in a great
variety of human tumors and tumor cell lines, such as
lung cancer, breast cancer, cervical carcinoma, ovarian
cancer, and so on [39-60]. It has been detected that the
functions of the FHIT gene are associated with tumor
development in 50 cases of gastric cancer (Huiping et al
[61]) and 84% of them have FHIT gene loss heterozygos-
ity. The FHIT gene reduces carcinogenesis of carcinoma
cells. However, the FHIT gene is considered as a carci-
noma suppressor gene. We speculate the role of FHIT in
inhibiting malignant transformation, [62] however, we
will further investigate FHIT in our research to prevent
cancer development.
Because FHIT is a protein-coding gene with its ultimate
product of fragile histindine triad protein that belongs to
the histindine triad protein family with carcinoma sup-
pression activity, FHIT gene mutation leads to FHIT pro-
tein abnormal expression. Various carcinogenic factors
also lead to abnormal FHIT protein expression, such as
reduced levels of FHIT protein expression [64]. FHIT pro-
tein deletion and the degrees of deletions in tissues are
closely linked to malignancies [5,6] and prognoses [65-
68] of tumors have detected pathological analyses.
Reduced expression took place in Stage II -III serous ovar-
ian cancer by Ozaki et al [69] but not in borderline serous
ovarian cystadenoma or other histology types of ovarian
cancer. It seems that FHIT protein is playing an important
role in the malignant course of serous ovarian cancer. The
findings of other types tumors also show that FHIT pro-
tein deletion or low expression suggests malignant trans-
formation, while on the contrary, high levels of FHIT
protein suggest benign status [33-35,37,48-60].
We are the first to systematically measure the expression
level of FHIT gene transcript and FHIT protein expression
in hypercortisolism of adrenocortical diseases. Found in
this study, expression of FHIT in adrenocortical carci-
noma is negative or weakly positive, and expression rate is
the lowest (P<0.0005). Expression of FHIT in adrenocor-
tical hyperplasia is strongly positive, and expression rate is
the highest (P<0.0005). Expression of FHIT in adrenocor-
tical adenoma is between carcinoma and hyperplasia. It
suggests that the degree of FHIT gene abnormal transcrip-
tion and FHIT protein deletion or reduction in adrenocor-
tical carcinoma is more serious than that in adenoma and
hyperplasia. FHIT gene abnormal transcript and FHIT pro-
tein deletion or reduction are closely linked to the malig-BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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nancies of tumors in hypercortisolism of adrenocortical
diseases. FHIT protein deletion or reduction might indi-
cate malignant transformation.
Found in this study, negative expression cases of adreno-
cortical carcinoma are 8 (57.14%), and weakly positive
expression cases are 6 (42.86%). It suggests that some-
times FHIT protein in malignant carcinoma is not com-
pletely deleted but reduced. It is thus that not all
adrenocortical carcinoma tissues expressed negative sig-
nals but some expressed weakly positive signals. The rea-
son might be linked to tumor malignant degree [65].
Because FHIT gene is a tumor suppressor gene, it can lead
cell apoptosis and growth inhabitations of tumors. In
some carcinomas with highly malignant degree, FHIT pro-
tein is deleted; in the carcinomas with lower malignant
degree, FHIT protein not completely deleted but reduced.
it appears feasible that we are able to design FHIT micro-
tubule assembles to suppress cell cycle and trigger cell
apoptosis in order to suppress tumor development [63] in
our future treatment plans.
Expression level and significance of Ki-67
Ki-67 nuclear antigen is a non-histone nucleoprotein in
proliferating cells' nucliues and is closely linked to cell
proliferation at region of tenth chromosome [70] in
human genome. Ki-67 is associated with tumor malignant
degree, tumor infiltrating, metastasis and recurrence. Ki-
67 is a tumor associated antigen that has tremendous
multiplication capacity and extensive influence on cell
proliferation. The function of Ki-67 in human genome
has not been identified completely but is linked to cell
karyokinesis. Regarded as framework of chromosomes,
Ki-67 may be non-histone nucleoprotein matrix inside of
chromosomes or around them. It appears that Ki-67 is an
important combined characteristic structured protein
with little IUP (intrinsic unstructured protein [109],
[111], [113]) regions that plays an essential role in keep-
ing the configuration of DNA [71]. Ki-67 is expressed in
proliferating cell nucleius at cell cycle stages such as G1
anaphase, S stage, G2 stage and M stage and is expressed
in all stages of cell cycle except G0. Because of its half-life
is short, Ki-67 degrade speedy when it out of cell cycle, so
it become one of the most effective targets of detecting
malignant tumor cell proliferation [72]. Results of
researches in this field showed that Ki-67 can reflect
malignant tumor cell multiplication capacity credibly and
speedily; Ki-67 is correlated with a great variety of malig-
nant tumor development, excessive inversion and prog-
nosis [7-10,73-77]. The level of Ki-67 expression is
roughly proportional to the degree of malignancy and
prognosis [78]. However, we consider Ki-67 is a malig-
nancy marker but is independent to prognosis as reported
in [79]. Ki-67 labeling index of ovarian adenocarcinoma
indicates significantly higher malignancy than low malig-
nant degree ovarian carcinoma [80]. Ki-67 positive cell
percent in high-grade ovarian adenocarcinoma is high,
and it is not correlated with tumors histological types, so
Ki-67 is useful of ovarian carcinoma's classification but
not highly characteristic. Ki-67 can label cells in G1 ana-
phase, S stage, G2 stage and M stage, but not G0 stage and
G1 forepart. It appears that the level of Ki-67 expression
can diagnose the malignant tumors but high multiplica-
tion capacity while pathological analysis encounters diffi-
culty. Therefore Ki-67 can distinguish benign from
malignant tumors. 9 cases of neighboring noncancerous
tissue then found that Ki-67 is regarded as a useful antigen
for detecting cell multiplication capacity [81].
Ki-67 is closely linked to differential diagnosis in hyper-
cortisolism of adrenocortical diseases [82]. But published
reports on it are few. In previous study we researched Ki-
67 express in 45 cases of adrenocortical tumors and 9
cases of neighboring noncancerous tissue found that
expression of Ki-67 is corrected with adrenocortical
tumor. Ki-67 may be taken as one of biomarkers for differ-
entiation of adrenocortical adenomas from adrenocorti-
Table 7: Expressions of Ki-67 and PCNA in adrenocortical 
diseases
ki-67 PCNA
(−) (+) (++) (+++)
(−)3 1 51 2 5
( + ) 0252
(++) 0 0 2 2
(+++) 0 0 0 1
Spearman's Correlation Coefficient: rs=0.387, p=0.006
Table 5: Expressions of FHIT and Ki-67 in adrenocortical 
diseases
FHIT Ki-67
(−) (+) (++) (+++)
(−) 0621
( + ) 2220
( + + ) 1 6 000
(+++) 17 1 0 0
Spearman's Correlation Coefficient: rs=-0.718, p<0.0005
Table 6: Expressions of FHIT and PCNA in adrenocortical 
diseases
FHIT PCNA
(−) (+) (++) (+++)
(−) 0153
( + ) 0023
( + + ) 1771
( + + + ) 2952
Spearman's Correlation Coefficient: rs=-0.449, p=0.001BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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cal carcinoma [84,85]. But in the previous study, the value
of Ki-67 for diagnosing adrenocortical carcinoma, adren-
ocortical adenoma and adrenocortical hyperplasia was
not analyzed.
Found in this study, expression rate of Ki-67 in adrenocor-
tical carcinoma is the highest (P<0.0005). It is evident that
cell proliferation of adrenocortical carcinomas is more
active than adenoma and hyperplasia. Cell proliferation is
directly linked to tumor malignancy. Cell proliferation
degree consists with tumor malignant degree. So Ki-67
expresses more obviously in adrenocortical carcinoma
than in adenoma and hyperplasia (P<0.0005). Because of
no abnormal proliferation in normal human tissue cells,
Ki-67 is expressed in all human normal cells. Expression
of Ki-67 in adrenocortical hyperplasia is not detectable,
but in adrenocortical adenoma it is somehow detectable.
Because cell proliferation is also observed in benign
tumors, even though the expression of Ki-67 in adreno-
cortical adenoma is low. Along with the cell proliferating
degree enhanced, positive grade and positive rate of Ki-67
expression in adrenocortical diseases are enhanced.
Because the degree of malignancy is closely linked to
tumor cell proliferating degree, Singer and other authors
[16,73,85,86] consider Ki-67 to have the ability of tumor
infiltrating. Since the expression of Ki-67 increases along
with the increasing degree of tumor infiltrating, they con-
sider that Ki-67 might be taken as a parameter to evaluate
the ability of tumor infiltrating. Results of this study sug-
gest the expression level of Ki-67 reflects the degree malig-
nancy.
Expression level and significance of PCNA
Proliferation cell nuclear antigen (PCNA) is a cell cycle
protein indispensable to coping of DNA chains. PCNA is
only expressed in proliferating cells. Because tumors pro-
liferate faster than normal cells, expression level of PCNA
can sensitively reflect the degree of tumor cell prolifera-
tion. PCNA is discovered recently as a candidate of tumor
marker that reflects cell proliferation degree. It is an anti-
gene specifically expressed in proliferating cell nucleius to
measure cells' multiplication capacity [87-90].
PCNA is a nucleoprotein with 36KD molecular weight. It
functions as an affiliated protein of DNA polymerase δ. It
is indispensable to the copy and rehabilitation of eucary-
ote DNA main chain and normal cell cycle. Results of
researches in this field showed that expression level of
Table 9: Quantifying of variable
Variable Targets Quantifying
Y Item Hyperplasia 0, adenoma 1, carcinoma 2
x1 Abdominal mass have=1, have not=0
x2 Decrease in bone content have=1, have not=0
x3 F4PM nmol/L
x4 ACTH8AM nmol/L
x5 Tumor size cm3
x6 Metastasis have=1, have not=0
x7 FHIT - 0 + 1 ++ 2 +++ 3
x8 Ki-67 - 0 + 1 ++ 2 +++ 3
x9 PCNA - 0 + 1 ++ 2 +++ 3
x10 Purple striae have=1, have not=0
x11 Urinary 17-KS μmol/L
Table 8: Compare with expression of FHIT, Ki-67, PCNA in adrenocortical diseases and clinical targets
FHIT P Ki-67 P PCNA P
Item n Total positive Total rate(%) Total positive Total rate(%) Total positive Total rate(%)
Age (year)
<40 30 25 83.33 0.959 9 30 0.511 29 96.67 0.296
≥40 19 15 78.95 14 73.68 17 89.47
Sex
Male 17 13 76.47 0.424 7 41.18 0.154 17 100 0.878
Female 32 27 84.38 7 21.88 29 90.63
Part
Left 28 22 78.57 9 32.14 26 92.86
Right 21 18 85.71 0.887 5 23.81 0.815 20 95.24 0.934BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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PCNA is linked to cell proliferation. PCNA expression in
cell nuclieus increases at G1 stage, reaches top at S stage,
decrease at G2 stage, but no expression at M and G0 stage.
PCNA plays an important role in the adjustment and copy
of DNA. PCNA is expressed only in proliferation cells, is
expressed much fewer in static cell. The expression level of
PCNA can reflect cells' multiplication capacity. PCNA is
measurable target for detecting degree of cell proliferation
[91].
We consider the degree of cell proliferation degree reflects
tumors' biological behaviors; excessive cell proliferation
can lead to tumor; cell proliferation is related to tumor
excessive invasion and metastasis; therefore tumor cell
proliferation can reflect tumor malignancy. PCNA is
closely linked to tumor biological behaviors and malig-
nancy [11-14]. High expression level of PCNA reflects
high degree of cell proliferation [92,93]. PCNA is related
to tumor classification, clinical phase, malignancy, metas-
tasis and prognosis [94]. It is plausible to use PCNA to
reflect tumor phase, recurrence and malignancy and clas-
sification [95]). It has been reported the detected PCNA
expression level in 23 cases of ameloblastoma, indicating
that PCNA Index of follicle formation type
(34.56%±14.00%) is of higher significance than plexi-
form type (24.44%±15.74%). It has been reported that
detections of Ag-NOR, PCNA and Ki-67 showed no differ-
ences in the degree of cell proliferation between follicle
formation type and plexiform type [96].
Yanxiaochu [97] et al detected cell proliferating degree in
54 cases of adrenocortical normal tissues, hyperplasia,
adenoma and carcinoma by DNA Content, Ag-NOR,
PCNA staining, and found that there was no difference
between adrenocortical normal tissues and hyperplasia
on DNA Content, Ag-NOR, PCNA Index (P>0.05). But
there was differences among adrenocortical hyperplasia,
adenoma and carcinoma (P<0.01). Our results support
and coincident with other findings. Found in this study,
expression level of PCNA in adrenocortical carcinoma is
the highest, and expression level in adrenocortical hyper-
plasia is the lowest. The expression level of adrenocortical
adenoma is in the middle (P<0.0005). From hyperplasia,
adenoma to carcinoma, while the degree of cell proliferat-
ing is increasing, the positive rate of PCNA expression is
also increasing too. Because the cell proliferating degree
between hyperplasia and adenoma is different, expression
level of PCNA can be considered as a marker for distin-
guishing adrenocortical adenoma and adrenocortical
hyperplasia.
The correlations among the expression levels of FHIT, Ki-
67 and PCNA
FHIT gene-coding protein is a carcinoma suppressor, it
can lead microtubule assembly; however, it can also sup-
press cell cycle, and may trigger cell apoptosis. In order to
suppress tumor proliferation, we must avoid low level of
expression of FHIT that limit microtubule assembly and
restrain cell apoptosis. Otherwise tumor hyperplasia may
overwhelmingly lead to malignancy. Ki-67 can label cells
in all stages of cell cycle except G0 as this antigen reflects
cell proliferation directly. The expression level of Ki-67
reflects tumor multiplication capacity. The role of Ki-67 is
opposite to FHIT. PCNA is mainly expressed in proliferat-
ing cell, and is expressed much fewer in static cell. So its
expression can also reflect cells' multiplication capacity.
The role of PCNA is similar to Ki-67 and is also opposite
to FHIT. Found in this study as shown in table 5, 6 and 7,
Table 11: Single factor ordinal logistic regression analysis
Factors Coefficient of regression Standard error Wald P
Constant 1 -7.06 2.401 8.646 0.003
Constant 2 1.942 1.733 1.255 0.263
FHIT -3.099 0.891 12.108 0.001
PCNA 2.089 0.752 7.712 0.005
Table 10: Single factor ordinal logistic regression analysis
Factors Coefficient of regression Standard error Wald P
Abdominal mass 3.265 1.172 7.757 0.005
Decrease in bone content -2.165 0.92 5.542 0.019
Blood cortisol 4PM -0.003 0.002 2.981 0.084
Blood ACTH 8AM -0.133 0.59 5.062 0.024
Tumor size 0.002 0.001 4.86 0.027
FHIT -2.904 0.72 16.267 <0.001
Ki67 3.262 0.905 12.198 <0.001
PCNA 1.912 0.479 15.906 <0.001BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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the expression levels of FHIT, Ki-67 and PCNA show dis-
tinct patterns in hypercortisolism of various adrenocorti-
cal diseases. The correlation between the expression of
FHIT and Ki-67 is negative. While the increasing cell pro-
liferating degrees among different diseases of Cushing's
syndrome, the expression level of tumor suppressor gene
FHIT is reduced, but tumor proliferating antigens Ki-67
and PCN are increased. The correlation between the
expression of FHIT and PCNA was negative. The correla-
tion between the expression of Ki-67 and PCNA is posi-
tive.
Because FHIT is a tumor suppressor gene, the expression
level of FHIT in adrenocortical hyperplasia is high, and in
adrenocortical carcinoma is low. On the contrary, expres-
sion levels of tumor proliferation cell nuclear antigens Ki-
67 and PCNA are roughly proportional to the cell prolif-
erating degree, their levels of expressions in adrenocortical
carcinoma are high and in adrenocortical hyperplasia are
low.
Expression levels of FHIT, Ki-67 and PCNA in the diagnosis 
of hypercortisolism
Found in this study, there are some rules in expression lev-
els of FHIT, Ki-67, and PCNA in hypercortisolism of vari-
ous adrenocortical diseases. When the expression of FHIT
is negative but both of Ki-67 and PCNA are strongly posi-
tive, adrenocortical carcinoma is suggested. Or when the
expression of FHIT is weakly positive, Ki-67 and PCNA is
both strongly positive, adrenocortical carcinoma is sug-
gested, too. When FHIT is strongly positive but both of Ki-
67 and PCNA are negative, adrenocortical hyperplasia is
suggested. Or when FHIT is strongly positive, Ki-67 is neg-
ative, PCNA is weakly positive, and adrenocortical hyper-
plasia is suggested, too. When FHIT, Ki-67 and PCNA are
all positive, adrenocortical adenoma is suggested. The
results of this study show that combined detection of the
expression of FHIT, Ki-67 and PCNA in hypercortisolism
of adrenocortical carcinoma, adenoma and hyperplasia is
valuable. They might be applied as credible markers for
distinguishing adrenocortical carcinoma, adrenocortical
adenoma and adrenocortical hyperplasia. Since those
rules are fairly complicated and are difficult for the oncol-
ogist who most likely receives only modest training in
molecular biology, we need to design an intelligent med-
ical diagnosis system to make a straightforward decision
that helps oncologists in their designing of treatment
plans.
The related factors of hypercortisolism of adrenocortical 
diseases
The related factors of the diagnosis of hypercortisolism of
various adrenocortical diseases have not been extensively
conducted and the differences of the related factors
among adrenocortical carcinoma, adenoma and hyper-
plasia have not been carefully analyzed up until now. Our
research represents the world's first systematic investiga-
tion of this type of disease. The values of the related fac-
tors in diagnosis of adrenocortical carcinoma have been
presented with limit scopes. Lidongxiao [98] et al studied
correlation risk factors of 55 cases adrenocortical knub
(including non function adenoma, pheochromocytoma,
aldosterone producing adenoma, cysts, punctatesub-
stance hemorrhage, yellow body hemorrhage, metastatic
carcinoma and so on, but not including adenoma). They
selected 9 factors including age, sex, BMI, knub diameter,
knub place, having hypertension or not, having diabetes
mellitus or not, having hormone secrete abnormally or
not, having other non adrenal tumor, they used statistical
analysis to find that knub diameter>2.4cm, mild-abnor-
mal hormone secretion, having hypertension were corre-
lation to the development of adrenal knub. Wubishi [99]
et al studied 81 cases hypercortisolism and found that the
clinical symptoms and signs such as acne, hairiness, pig-
mentation, oligomenorrhea or amenorrhea and oste-
oporosis in adrenocortical hyperplasia (Cushing
syndrome) were overwhelmingly outnumbered adreno-
cortical adenoma. Wangaiping [100] et al studied the dis-
eases using diagnostic values of endocrine laboratory in
70 cases of hypercortisolism. They found that the factors
including blood ACTH, blood cortisol, 24hUFC level and
large-dose dexamethasone suppression test of inhibition
or not were very important to diagnose hypercortisolism
diseases. Bornstein [101] et al also found that blood
ACTH and large-dose dexamethasone suppression test of
inhibition or not played an important role in diagnose
hypercortisolism diseases.
In this study 39 factors were investigated including com-
mon clinical information such as: sex, age, disease on left
or right, last time of disease; clinical symptoms and signs:
abdominal mass, hypertension, central obesity, moon
face, buffalo hump, plethoric face, purple striae, hairiness,
Table 12: Accuracies on Our System using Ensemble Methods, Decision Tree and SVM etc. Classifiers on Test Data Set for diagnosis of 
Cushing's Syndrome of Various Diseases
Performance Ensemble Methods SOM Decision Trees SVM
Average Accuracy 92.6% 86.4% 83.3% 81.7%
Standard Deviation 1.8% 2.4% 4.1% 3.6%BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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weakness, decrease in bone content, ECG abnormity and
arteriosclerosis, impaired glucose tolerance, infections,
oligomenorrhea or amenorrhea, edema, acne, petechia,
headache, decrease in bone content, renal calculi, thin
skin, bellyache, myoatrophy; laboratory findings: blood
potassium, blood cortisol (8AM, 4PM, 0AM), blood
ACTH (8AM, 4PM, 0AM), 24h urinary 17-OH, 24h uri-
nary 17-KS; medical images: observed tumor size by B-
ultrasonic tomography, CT, MRI, PET (if any); Immuno-
histochemical staining: expression of FHIT, Ki-67, PCNA
in adrenocortical diseases. We Analyzed the factors by sin-
gle factor logistic regression model, and found that 8 fac-
tors are likely related to hypercortisolism of
adrenocortical diseases including abdominal mass,
decrease in bone content or fracture, blood cortisol level
(4PM), blood ACTH level (8AM), tumor size, FHIT, Ki-67,
PCNA. We also analyzed those factors by multiple factor
logistic regression model, and found that the factors of
FHIT and PCNA are most valuable. The results suggested
that FHIT and PCNA are the more closely related factors
for diagnose of hypercortisolism of various adrenocortical
diseases. The main reason is the statistical correlation
between other factors and these 2 factors are too close.
There rest 6 factors are also somehow useful as well.
Clinically, tumor size is often considered as a marker for
distinguishing benign or malignant tumor. The diameter
of adrenocortical tumor over 5 cm suggests the tendency
of malignancy [102]. The place of adrenal glands is deep
in abdominal cavity. Too small tumor cannot be touched
easily. Touchable abdominal mass means the tumor size
is large. Abdominal mass is touchable or not and tumor
size contribute to diagnosing hypercortisolism of various
adrenocortical diseases. Over half of hypercortisolism
patients show decrease in bone content or fracture. Adren-
ocortical carcinoma patients show more significant
decrease in bone content and pathologic fractures are
more obviously (still not quite distinct). The reason is
likely linked to bone content loss and osteo-anabrosis.
But the correlations of decreases in bone content or frac-
ture and tumor malignancy have not been observed at
present. Clinically, the hypercortisolism patients' blood
cortisol level is often elevated and dysfunction both at
8AM, 4PM and 0AM. The report about differential 4PM
cortisol level has not been confirmed because it looks sus-
ceptible. In this study, 4PM cortisol level is likely a related
factor of hypercortisolism. It suggests dysfunction degree
of 4PM cortisol level in adrenocortical carcinoma is more
serious than adenoma and hyperplasia. Among hypercor-
tisolism, adrenocortical carcinoma, adenoma and hyper-
plasia secreting cortisol freely, high blood cortisol level
inhibits pituitary secreting ACTH and making blood
ACTH level decreased. 8AM blood ACTH level is sug-
gested a likely marker for distinguishing adrenocortical
carcinoma, adenoma and hyperplasia.
The high expression level of tumor suppressor gene FHIT
may suggest benign tumor. FHIT protein is an accessible
target in molecular biology laboratory used to judge vari-
ous benign tumors. The expression of cell proliferation
antigen Ki-67 reflects cell multiplication capacity. Ki-67
can reflect the proliferation rate of malignant tumors. Pro-
liferation cell nuclear antigen PCNA is also an accessible
target in molecular biology laboratory to assess the degree
of cell proliferation. The expression levels of FHIT, Ki-67
and PCNA in hypercortisolism of various adrenocortical
diseases are useful for distinguishing adrenocortical carci-
noma, adenoma and hyperplasia but none of them are
high characteristic. Therefore this again confirm the needs
of an intelligent medical decision system. This study
found there are some rules in expression levels of FHIT,
Ki-67, and PCNA in hypercortisolism of various adreno-
cortical diseases. We utilized them jointly in designing an
intelligent medical decision system to diagnose hypercor-
tisolism of adrenocortical carcinoma, adenoma and
hyperplasia. Because hypercortisolism is a common endo-
crine disease with increasing occurrence rate recently,
development of this medical diagnosis system is impor-
tant for choosing correct treatment plans and estimating
prognosis. The clinical significance of this medical deci-
sion system using expression levels of FHIT, Ki-67 and
PCNA and 5 related factors is that this system concurred
the difficulties of diagnosing hypercortisolism of various
adrenocortical diseases.
Conclusions
The novel intelligent medical diagnose system developed
here is originated from a prototype system that we won a
novel smart engineering system design award [108]. The
new system presented here has significantly enhanced the
diagnose of Cushing's syndrome of different diseases that
challenges today's medicine, the synergistic effects of the
system proved the great effectives of combined artificial
intelligence with experimental molecular biology tech-
nique. We benchmark our ensemble method against 3
other popular algorithms namely SOM, decision trees C5
and support vector machines SVM-light (table 13). Our
intelligent system significantly outperformed those popu-
lar machine learning algorithms and exceed 92% accuracy
in diagnosis. Along the way, we made several medical dis-
coveries:
1) The expression of FHIT, Ki-67 and PCNA strongly relate
to hypercortisolism of different adrenocortical diseases.
Expression of FHIT is the highest in adrenocortical hyper-
plasia, lowest in carcinoma, and middle in adenoma.
Expression of Ki-67 and PCNA in adrenocortical carci-
noma is the highest, in hyperplasia is the lowest, and in
adenoma is the middle. They might be applied as one of
markers for distinguishing adrenocortical carcinoma, ade-
noma and hyperplasia.BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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2) The expressions of FHIT, Ki-67 and PCNA in hypercor-
tisolism of adrenocortical diseases were paired correlated.
The correlation between the expression of FHIT and Ki-67
was negative; the correlation between the expression of
FHIT and PCNA was negative; the correlation between the
expression of Ki-67 and PCNA was positive.
3) The combined expression of FHIT, Ki-67 and PCNA in
hypercortisolism of adrenocortical diseases is valuable.
When the expression of FHIT is negative or weakly-posi-
tive but both of Ki-67 and PCNA are strongly positive,
adrenocortical carcinoma is suggested; when FHIT is
strongly positive but both of Ki-67 and PCNA are nega-
tive, adrenocortical hyperplasia is suggested; while when
FHIT, Ki-67 and PCNA are all positive, adrenocortical ade-
noma is suggested.
4) It was found by Logistic Regression that 8 factors were
likely linked to the diagnosis of hypercortisolism of
adrenocortical diseases including FHIT, Ki-67, PCNA,
abdominal mass, tumor size, decrease in bone content or
fracture, blood cortisol level (4PM), blood ACTH level
(8AM) amongst which FHIT and PCNA are the most
imprtant features for diagnosis.
The successful development of the world first of its kind
intelligent medical diagnosis system marks the beginning
of synergistic approaches of artificial intelligence and lab-
oratory molecular biology to diagnose diseases with high
accuracy.  The success may predict prognosis and better
understanding human genome mechanisms relating to
potential malignant transformation.  It also in provides
useful information for better treatment planning and can-
cer prevention.
Methods
The intelligent medical diagnostic system
Recently there has been a surge of interest in using ensem-
ble methods to enhance the performance of medical diag-
nostic systems. Ensemble method is a diverse class of
methods that seek to combine the decisions of several
(computational intelligence) classifiers in order to
improve the performance of the classification task. This
class includes:
Consensus networking – In this approach, the test
instances are fed into several (computational intelligence)
classifiers and majority voting of the classification deci-
sions of these classifiers are taken.
Boosting – This approach is a computational intelligence
machine learning meta-algorithm. At each boosting
round, a “weak” learner is trained with the data and output
of the learner is feedback to the learned function, with
some strength. Then, the data is re-weighted and boosting
is focused on the data that are difficult to learn in the next
boosting round, so that future “weak” learners will
attempt to reduce the mis-classification errors.
Bootstrap Aggregation (“Bagging”) – In this approach, the
original data set is sampled (with replacement) to form M
“bags” of data, each equal in size to the original dataset; a
classifier is constructed based on each of M bags. Then,
given an instance to be classified, it can be fed it into each
of the M classifiers and take the majority vote of these clas-
sifiers to form the final classification decision.
Ensemble methods have been shown to be effective at
reducing the generalization error. Several issues arise in
the design of such a medical decision system:
￿ What types of classifiers should be combined? And
￿ How should they be combined?
As to the first question, our system combines the predic-
tions of decisions from Recursive Maximum Contrast
Trees RMCT [106,107], SOFM and Parallel Self-Organzing
Hierarchical Neural Networks (PSHNN)[104,105]. As to
the second question, we are investigating a multistage
classification scheme in which each stage is composed of
multiple classifiers whose decisions are combined by
majority voting and consensus. Instances that are misclas-
sified by the first stage are passed to the second stage. The
idea is: by only focusing on the instances misclassified by
the first stage, the second stage can concentrate on the
more difficult parts of the feature space and so on. It
appears that there is a strong theoretical basis that Boost-
ing with Bagging [112] reduces the variance component of
the error under certain conditions and is resistant to over-
fitting. This is especially important that we are dealing
with a very important but kind of rare type of tumor that
is unsuited for a large training sample size (along with all
the expensive laboratory measures). We use a variant of
ensemble method that is a diverse class of methods that
seek to combine the decisions of several computational
intelligence classifiers in order to improve the perform-
ance of the classification task. Our algorithm is as follows:
￿ First step:
– Construct two very different computational intelligence
classifiers, the variant of the neural network Self-Organiz-
ing Feature Map (SOFM) classifier and RMCT.
– Pass the test instance to both classifiers:
- If both classifiers agree, then this is the consensus predic-
tion.BMC Genomics 2008, 9(Suppl 1):S23 http://www.biomedcentral.com/1471-2164/9/S1/S23
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- If they disagree, this may indicate that the instance is dif-
ficult to predict reliably, then we use the second step with
additions of a third classifier and a more powerful compu-
tational intelligence algorithm named Boosting with Bag-
ging to break the tie (we will explain the Boosting with
Bagging algorithm in a separate section later on).
￿ Second step:
– Construct an additional classifier, PSHNN.
Pass the test instance to all 3 classifiers (SOFM, RMCT and
PSHNN), but each classifier is also trained by Boosting
with Bagging; the consensus prediction is obtained by tak-
ing the majority vote of all three classifiers.
A medical decision system or a medical expert system can
use Kohonen's SOM. Our development of new variants of
neural network based algorithms is Self-organizing Fea-
ture Map algorithms (SOFM) and is inspired by the SOM
[103] and the PSHNN (Parallel Self-Organizing Hierarchi-
cal Neural Networks) algorithms [103,104]. The compu-
tational intelligence system we developed here is a
machine learning system rather a medical expert system
(which is a much more sophisticated system governed by
the rules based on the opinions from the experts in a spec-
ified field). Though our system is relatively simpler and
more straightforward than an expert system, it can actu-
ally be more useful and more accurate for a well-defined
highly specific task because all features are the solid exper-
imentally measured gene expression and clinical measure-
ment values rather than diverse opinions from human
experts or predicted gene expression values from pure bio-
informatics software tools.
In the Kohonen's neural networks SOM algorithm, each
neuron has associated with a topological neighborhood,
and the algorithm is such that neighboring neurons in the
topological space tend to arrange themselves over time
into a grid in feature space that mimics the neighborhood
structure in the topological space. The SOFM algorithm
differs from the Kohonen's neural networks SOM algo-
rithm by dropping the topological neighborhood and
replacing it with the concept of a global neighborhood
generated by ranking with two significant variants. When-
ever the SOFM and RMCT in the Consensus Networking
machines gave conflicting decisions, we needed addi-
tional computational intelligence algorithms to break the
tie. This motivated us to develop the Boosting with Bag-
ging algorithm that is applied to SOFM, RMCT and
PSHNN for the final majority voting decision. Boosting is
a computational intelligence algorithm that can be com-
bined with Bagging to improve the performance of a clas-
sifier. When combined appropriately, Boosting with
Bagging is resistant to overfitting. While the original
boosting algorithm is due to Schapire, later Freund and
Schapire introduced an improved algorithm called Ada-
boost that was designed to handle 2-class classifiers. There
were several extensions to the multiclass case, including
Adaboost.M1. As we are interested in incorporating useful
confidence information into a classifier, we combine bag-
ging with a generalization of traditional boosting algo-
rithm that allows confidence information to be
incorporated. Our combined Boosting with Bagging algo-
rithm emphasizes weaker learner for each boosting run.
Assuming we have N training instances, then we construct
classifying function  . Class label yi is either 0 or 1.
The square error of classifier   is given by:
The procedure of Boosting with Bagging is described as
following
￿ Initialization:
where i = 1, 2, 3,…, N; N is the number of training
instances;
Wi is the weight of training instance; Pi is the probability
of instance.
￿ For t = 1 to T, take n subsamples, choose one of subsam-
ples that gives smallest error.
Update coefficient αt, weight Wi of training instance and
probability Pi of instance at t boosting round.
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￿ The confidence instance   belonging? to class k is deter-
mined by the following equation: 
Bagging with boosting will reduce variance error but will
not affect bias error. It can be verified as following:
Assume that we want to form an estimator of a quantity
based on observations. We can express the error of this
estimate as the sum of a variance component and a bias
component. Let us assume observations
 Estimator   and cor-
responding true  . Thus
And there are m observed estimators:
, average their predictions to obtain
an overall estimation. The variance of the overall estimate
is:
while the bias of the overall estimate is:
Therefore, we can see that variance of the overall estimator
is reduced, while the bias remains roughly the same.
Improving the predicting power of computational 
intelligence by feature filtering and feature selection
In classification problems, we are often interested in max-
imizing the true positive rate (also called the sensitivity),
as this rate reflects the ability of the classifier to detect the
“signal”. For example, we designed this computational
intelligence system classifier to indicate whether or not a
given patient has malignant cancer (in this case the “sig-
nal” is “having malignant carcinoma”), then the cost of
saying that the patient does not have malignant carci-
noma when in fact the patient does (the false negative
rate) is much higher than the cost of saying that the
patient has malignant cancer when in fact the patient does
not (the false positive rate). Thus, it is more important to
make the false negative rate smaller and lower than the
false positive rate. Since true positive rate = 1—false nega-
tive rate and true negative rate = 1—false positive rate, it is
desirable in many applications to make the true positive
rate (i.e. the sensitivity) larger at the expense of the true
negative rate (i.e. the specificity). Sensitivity makes the y-
axis and (1-specificity) makes the x-axis in Receiver Oper-
ating Characteristic (ROC) curve. A complete prefect ran-
dom “classifier” gives a diagonal line with Youden Index
= 0 (Youden index is the sensitivity + specificity—1),
while a perfect deterministic classifier always gives both
sensitivity and accuracy equal to 1 with Youden Index = 1.
A large ROC area and a large Youden Index indicate a
good classifier. In our case, a true positive corresponds to
the case of correctly classifying a malignant cancer patient.
Malignant cancers tend to be less distinctive than benign
compare to normal tissues. Characteristic tumor associ-
ated gene expressions may turn out to have desirable
properties that can be used to enhance sensitivity at the
expense of specificity. To qualify for features (measured
by experiments) in our classifier, any two features must
not be statistically correlated, must give a satisfactory dis-
tance separation in the feature space (between classes)
and must offer good generalization for the predictor [110-
112].  The system we developed satisfies the above criteria
and is a useful tool for enhancing accuracy upon diagnos-
ing diseases and predicting prognosis.
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